QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study

BMC Infectious Diseases

Fekadu Abebe⁴  Gunnar Bjune⁴  Girmay Medhin³  Yonas Bekele¹  Adane Mihret¹  Daniel Dagne²  Mengistu Legesse³  Mulugeta Belay⁴ 

[1] Armauer Hansen Research Institute, Addis Ababa, Ethiopia;Dessie Regional Health Research Laboratory Center, Amhara Regional Health Bureau, Dessie, Ethiopia;Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia;Department of Community Medicine, Institute of Health and Society, University of Oslo, Blindern 0318, Oslo, Norway

关键词: Ethiopia;    Contacts;    Patients;    Reversion;    Conversion;    QuantiFERON-TB-Gold In-Tube;    Tuberculosis;   

Others  :  1125373
DOI  :  10.1186/s12879-014-0654-5

 received in 2014-07-30, accepted in 2014-10-29,  发布年份 2014

【 摘 要 】

Background

QuantiFERON-TB Gold In-Tube® (QFT-GIT) test is used for the diagnosis of latent tuberculosis (TB) infection. Besides, QFT-GIT test could allow tracking changes in immune response among TB patients and their contacts. In high TB burden settings, reports on QFT-GIT conversions and reversions among TB patients and their contacts are limited. As part of a major project to study immune responses to TB infection, we investigated QFT-GIT test conversions and reversions among smear positive pulmonary TB patients and their household contacts over 12 months.

Methods

We followed a total of 107 HIV negative participants (33 patients and 74 contacts) in Addis Ababa. We did QFT-GIT test at baseline and 12 months later according to the manufacturer’s instructions.

Results

At baseline, 25/33 (75.8%) of the patients and 50/74 (67.6%) of the contacts were QFT-GIT positive. At 12 months, 2 more patients (1 test negative and 1 indeterminate) became test positive. Besides, 11/24 (45.8%) test negative contacts became positive. Only one patient and one contact who were test positive at baseline became test negative 12 months later. At 12 months, the proportions of QFT-GIT test positives for patients and contacts were, therefore, 78.8% and 81.1%, respectively. Among contacts, the proportion of QFT-GIT test positives at 12 months was significantly higher compared to the corresponding proportion at baseline (McNemar, p = 0.006); similarly, the median IFN-γ response significantly increased at 12 months compared with the baseline level (Wilcoxon matched-pairs signed rank test, p = 0.01). Patients, however, had comparable median IFN-γ levels at baseline and 12 months later (p = 0.56).

Conclusion

Nearly half of QFT-GIT negative household contacts at baseline became positive at 12 months. This suggests that repeated screening of QFT-GIT negative contacts may be needed for epidemiological studies and interventions of latent TB in an endemic setting. A large longitudinal study may be needed to confirm our observations.

【 授权许可】

   
2014 Belay et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Global Tuberculosis Report. WHO, Geneva; 2013.
• [2]The STOP TB STRATEGY: Building on and Enhancing DOTS to Meet the TB-Related Millennium Development Goals. WHO, Geneva; 2006.
• [3]Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D: The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol 2011, 40(4):964-970.
• [4]Hart PD, Sutherland I: BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1977, 2:293-295.
• [5]Guidelines for Clinical and Programmatic Management of TB, Leprosy and TB/HIV in Ethiopia. MOH, Addis Ababa; 2012.
• [6]Menzies D: Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999, 159(1):15-21.
• [7]Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149(3):177-184.
• [8]Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007, 146(5):340-354.
• [9]Lee SW, Lee SH, Yim JJ: Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. Infection 2012, 40(4):431-435.
• [10]Ringshausen FC, Nienhaus A, Schablon A, Schlosser S, Schultze-Werninghaus G, Rohde G: Predictors of persistently positive Mycobacterium-tuberculosis -specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 2010, 10:220. BioMed Central Full Text
• [11]Shah M, Kasambira TS, Adrian PV, Madhi SA, Martinson NA, Dorman SE: Longitudinal analysis of QuantiFERON-TB gold in-tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study. PLoS One 2011, 6(10):e26787.
• [12]Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, Hussey GD, Mahomed H: Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012, 186(10):1051-1056.
• [13]Summary and Statistical Report of the 2007 Population and Housing Census Results. CSA, Addis Ababa; 2007.
• [14]Guidelines for HIV Counselling and Testing in Ethiopia. MOH, Addis Ababa; 2007.
• [15]Jensen AV, Jensen L, Faurholt-Jepsen D, Aabye MG, Praygod G, Kidola J, Faurholt-Jepsen M, Changalucha J, Range N, Krarup H, Friis H, Andersen AB: The prevalence of latent Mycobacterium tuberculosis infection based on an interferon-gamma release assay: a cross-sectional survey among urban adults in Mwanza, Tanzania. PLoS One 2013, 8(5):e64008.
• [16]Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, Reddy MV, Kalantri A, Hill PC, Menzies D, Hopewell PC: T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009, 13(1):84-92.
• [17]Legesse M, Ameni G, Mamo G, Medhin G, Bjune G, Abebe F: Community-based cross-sectional survey of latent tuberculosis infection in afar pastoralists, Ethiopia, using QuantiFERON-TB Gold In-tube and tuberculin skin test. BMC Infect Dis 2011, 11:89. BioMed Central Full Text
• [18]Belay M, Bjune G, Ameni G, Abebe F: Diagnostic and treatment delay among Tuberculosis patients in Afar Region, Ethiopia: a cross-sectional study. BMC Public Health 2012, 12:369. BioMed Central Full Text
• [19]Mahan CS, Zalwango S, Thiel BA, Malone LL, Chervenak KA, Baseke J, Dobbs D, Stein CM, Mayanja H, Joloba M, Whalen CC, Boom WH: Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. Am J Trop Med Hyg 2012, 86(4):690-697.
• [20]Aichelburg MC, Reiberger T, Breitenecker F, Mandorfer M, Makristathis A, Rieger A: Reversion and conversion of interferon-gamma release assay results in HIV-1-infected individuals. J Infect Dis 2014, 209(5):729-733.
• [21]Kebede AH, Alebachew Z, Tsegaye F, Lemma E, Abebe A, Agonafir M, Kebede AJ, Demissie D, Girmachew F, Yaregal Z, Dana F, Getahun M, Fiseha Y, Meaza A, Dirse N, Timimi H, Sismanidis C, Tadolini M, Onozaki I: The first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011. Int J Tuberc Lung Dis 2014, 18(6):635-639.
• [22]Hur YG, Gorak-Stolinska P, Lalor MK, Mvula H, Floyd S, Raynes J, Ben-Smith A, Fitchett JR, Flanagan KL, Burl S, Ota MO, Crampin AC, Smith SG, Dockrell HM: Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK. BMC Infect Dis 2014, 14:184. BioMed Central Full Text
• [23]Rakotosamimanana N, Raharimanga V, Andriamandimby SF, Soares JL, Doherty TM, Ratsitorahina M, Ramarokoto H, Zumla A, Huggett J, Rook G, Richard V, Gicquel B, Rasolofo-Razanamparany V: Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Clin VaccineImmunol 2010, 17(7):1094-1103.
• [24]Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah D, Lugos MD, Donkor SA, Adegbola RA, Brookes RH: Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006, 6:66. BioMed Central Full Text
• [25]Komiya K, Ariga H, Nagai H, Kurashima A, Shoji S, Ishii H, Nakajima Y: Reversion rates of QuantiFERON-TB Gold are related to pre-treatment IFN-gamma levels. J Infect 2011, 63(1):48-53.
• [26]Lee SW, Lee CT, Yim JJ: Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis 2010, 10:300. BioMed Central Full Text
• [27]Orme IM: A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis 2014, 94(1):8-14.
• [28]Denkinger CM, Pai M, Patel M, Menzies D: Gamma interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory. J Clin Microbiol 2013, 51(2):607-610.